Familial hypomagnesaemia with secondary hypocalcaemia: novel TRPM6 variant

Rita Alvelos1,2, João Nico2,3, Marta Machado2

  • 1Paediatric Service, Local Health Unit of the Aveiro Region, Aveiro, Portugal ritalvelos@gmail.com.

BMJ Case Reports
|November 11, 2025
PubMed

Familial hypomagnesaemia with secondary hypocalcaemia (HSH) is an autosomal recessive disease caused by mutations in the Transient Receptor Potential Melastatin 6 (TRPM6) gene. It manifests with severe hypomagnesaemia and hypocalcaemia, and its most common clinical presentation is seizures in early infancy. This is a case of an infant with HSH who presented with seizures. Investigation disclosed hypocalcaemia and hypomagnesaemia with undetectable calcitonin and normal parathyroid, and thyroid hormones and vitamin D. Only after a second admission was she discharged on long-term oral magnesium (Mg) supplementation. Genetic investigation revealed a novel variant in the TRPM6 gene. At the last consultation, the patient remained asymptomatic, without any complications, under Mg supplementation. Different homozygous mutations have been described in HSH. However, this case describes the presence of two heterozygous variants: c.5785del p.(Glu1929LysfsTer3), and c.3179T>A p.(Ile1060Asn). HSH might be responsible for permanent neurological sequelae. Nevertheless, the prognosis is good if diagnosis and treatment are established early.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
6.0K